ArticleCell communication and signaling : CCS2026
Precise metabolomics identifies glycolysis-related pyruvate kinase M activity as regulator of the S-phase-specific radiation response in triple-negative breast cancer cells.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic reprogramming is known to critically contribute to therapy response in cancer, including the resistance of triple-negative breast cancer (TNBC) patients to conventional radio/(chemo)therapy. Our study, therefore, characterized the metabolic response of TNBC cell models to irradiation using untargeted metabolomics. We identified radiation-induced metabolic changes by harnessing a metabolite-gene interaction network comprising 44 genes. Nine genes with significant radiosensitizing potential in TNBC cells were identified by RNAi-screening. Among the druggable genes, high expression of pyruvate kinase M (PKM) was associated with worse overall survival in the METABRIC-TNBC cohort. Pharmacological PKM inhibition led to radiosensitization in TNBC cell models, which was attributed to S-phase related metabolic changes. Selective disruption of the S-phase by PKM inhibition led to both reduced DNA synthesis and increased replication stress, as evidenced by increased DNA damage at active replication forks. This resulted in prolonged cell cycle arrest after irradiation. Metabolic profiling upon PKM depletion and irradiation revealed two positively PKM-associated gene clusters, predominantly involved in the glycolysis pathway. Each cluster was functionally distinct, one shared the PKM-associated effects in survival reduction, while the other correlated with its radiosensitization. High expression of the first cluster was significantly correlated with worse overall survival, whereas high expression of the second cluster, consisting of PKM, ENO1, GAPDH and GPI, predicted poor response to radiotherapy in the METABRIC-TNBC cohort. Thus, our study suggests that glycolytic-associated metabolic reprogramming upon irradiation plays a major role in radioresistance of TNBC. Analysis of our identified glycolysis-related gene cluster in patients could predict the response to radiotherapy, and targeting PKM and the related glycolytic pathway holds promise for radiosensitization in TNBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.